Lexology December 5, 2024
The 2024 election results will create significant tailwinds for Republican legislative and regulatory priorities in US Congress, federal agencies, and state houses across the country. This On the Subject considers the outlook for pharmacy regulation under the second incoming Trump administration and a unified Republican Congress, as well as state-level pharmacy policies that may advance as Republican public policy momentum builds.
In Depth
In its second term, the Trump administration is likely to pursue many of the priorities left unfinished at the end of its first term. With respect to pharmacy regulation, during President-elect Trump’s first term, Congress enacted the Know the Lowest Price Act and the Patients’ Right to Know Drug Prices Act. These two acts prohibited “gag clauses”...
Today's Sponsors
Today's Sponsor